HighTower Advisors LLC Has $727,000 Position in Repligen Co. (NASDAQ:RGEN)

HighTower Advisors LLC reduced its stake in Repligen Co. (NASDAQ:RGEN) by 3.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,054 shares of the biotechnology company’s stock after selling 180 shares during the period. HighTower Advisors LLC’s holdings in Repligen were worth $727,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the 3rd quarter valued at $37,000. Quarry LP lifted its position in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. grew its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the period. Global Retirement Partners LLC boosted its stake in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $133.41 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business has a 50-day simple moving average of $154.21 and a two-hundred day simple moving average of $148.14. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $184.98. The firm has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on RGEN shares. Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.